14.4 Cardiovascular Outcomes Trial of OZEMPIC in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease SUSTAIN 6 (NCT01720446) was a multi-center, multi-national, placebo-controlled, double-blind cardiovascular outcomes trial
When caloric intake drops substantially, particularly if protein intake is inadequate, patients may experience fatigue, weakness, and reduced physical stamina
The primary weight-loss endpoint was not met
Symptoms of thyroid cancer (a lump or swelling in your neck, hoarseness, trouble swallowing)
To view or add a comment, sign in More Relevant Posts Access to appropriate healthcare is still far from equitable
In stark contrast, dietary supplements marketed as "GLP-1" products are regulated under the Dietary Supplement Health and Education Act (DSHEA) of 1994, which places the burden of safety on manufacturers rather than requiring pre-market approval